Twenty-nine states sued Bristol-Myers Squibb Co. on Tuesday, accusing the maker of the cancer drug Taxol of fraudulently keeping less-expensive generic versions off the market. The suit alleged that the pharmaceutical company obtained patents for Taxol under false pretenses and delayed generic versions from coming on to the market, forcing hospitals, patients and states to pay more for the medicine.
June 05, 2002 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
ABOUT THIS RECRUITMENTOur attorneys face some of the most challenging, cutting-edge legal issues in the environmental field. As such, we ar...
Hofstra University enrolls over 6,000 undergraduate students and nearly 4,000 graduate students in 13 schools, which feature a variety of de...
McCarter & English, LLP is actively seeking a patent associate, patent agent, or technical specialist for its Intellectual Property Prac...
